https://bioinformatics.umg.eu/onkopus/drugon#immunologicalagentinterleukininhibitor
Properties
- label
- [] immunological agent--interleukin inhibitor
Parents
Children
Relations
- is_kegg_class
- siltuximab
- is_kegg_group
- reslizumab
- is_kegg_group
- mirikizumab
- is_kegg_group
- tocilizumab
- is_kegg_group
- secukinumab
- is_kegg_class
- antithymocyteimmunoglobulinrabbit
- is_kegg_class
- basiliximab
- is_kegg_class
- satralizumab
- is_kegg_group
- brazikumab
- is_kegg_class
- ixekizumab
- is_kegg_group
- basiliximab
- is_kegg_class
- guselkumab
- is_kegg_class
- tildrakizumab
- is_kegg_class
- dupilumab
- is_kegg_class
- secukinumab
- is_kegg_group
- brodalumab
- is_kegg_group
- spesolimab
- is_kegg_class
- reslizumab
- is_kegg_group
- etokimab
- is_kegg_group
- tildrakizumab
- is_kegg_class
- bimekizumab
- is_kegg_class
- mepolizumab
- is_kegg_class
- anakinra
- is_kegg_group
- lusvertikimab
- is_kegg_group
- risankizumab
- is_kegg_group
- lisofylline
- is_kegg_group
- olokizumab
- is_kegg_class
- ustekinumab
- is_kegg_group
- lutikizumab
- is_kegg_group
- pirfenidone
- is_kegg_class
- spesolimab
- is_kegg_group
- depemokimab
- is_kegg_group
- antithymocyteimmunoglobulinrabbit
- is_kegg_group
- apilimodmesylate
- is_kegg_class
- risankizumab
- is_kegg_group
- mepolizumab
- is_kegg_group
- rilonacept
- is_kegg_group
- fezakinumab
- is_kegg_class
- brodalumab
- is_kegg_group
- siltuximab
- is_kegg_group
- sarilumab
- is_kegg_group
- satralizumab
- is_kegg_group
- tibulizumab
- is_kegg_group
- briakinumab
- is_kegg_group
- ustekinumab
- is_kegg_group
- lebrikizumab
- is_kegg_class
- mirikizumab
- is_kegg_group
- canakinumab
- is_kegg_group
- sirukumab
- is_kegg_class
- sarilumab
- is_kegg_group
- daclizumab
- is_kegg_class
- pirfenidone
- is_kegg_class
- rilonacept
- is_kegg_group
- dupilumab
- is_kegg_group
- ixekizumab
- is_kegg_group
- nemolizumab
- is_kegg_group
- anrukinzumab
- is_kegg_class
- nemolizumab
- is_kegg_group
- izokibep
- is_kegg_class
- benralizumab
- is_kegg_group
- enokizumab
- is_kegg_group
- bimekizumab
- is_kegg_group
- gevokizumab
- is_kegg_class
- canakinumab
- is_kegg_group
- anakinra
- is_kegg_class
- tocilizumab
- is_kegg_group
- tralokinumab
- is_kegg_group
- ordesekimab
- is_kegg_group
- itepekimab
- is_kegg_class
- tralokinumab
- is_kegg_group
- isunakinra
- is_kegg_group
- afasevikumab
- is_kegg_group
- tozorakimab
- is_kegg_group
- benralizumab
- is_kegg_group
- guselkumab